Streptomyces Aureofaciens Patents (Class 435/889)
  • Patent number: 5965429
    Abstract: Recombinant S. aureofaciens cells are provided. These cells comprise: (a) at least one CTC 11 gene; and (b) optionally(i) a CTC 09 gene;(ii) a CTC 03 gene; or(iii) a combination thereof;wherein:the CTC 11 gene is chromosomal, extra-chromosomal, or chromosomal and extra-chromosomal;the CTC 09 gene, CTC 03 gene, or a combination thereof is chromosomal, extra-chromosomal, or a combination thereof; expression of the CTC 11 gene is enhanced over that of a wild-type S. aureofaciens cell; andoptionally, the CTC 09 gene, the CTC 03 gene, or both of the CTC 09 gene and the CTC 03 gene are inactivated.The present invention also contemplates vector pLP21329 and vectors for allelic replacement in a S. aureofaciens host cell. The vectors comprise:(a) a functional E.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: October 12, 1999
    Assignee: American Cyanamid Company
    Inventor: Michael J. Ryan
  • Patent number: 4921801
    Abstract: Novel recombinant DNA cosmid shuttle vectors and a method of using them in the construction of genomic DNA libraries are described. The vectors demonstrate the incorporation of both the size selection and in vitro packaging mechanisms of lambda into a Streptomyces-E. coli shuttle vector by the incorporation of two or more COS sequences of bacteriophage lambda.
    Type: Grant
    Filed: March 20, 1986
    Date of Patent: May 1, 1990
    Assignee: Eli Lilly and Company
    Inventors: R. Nagaraja Rao, Richard K. Stanzak
  • Patent number: 4843002
    Abstract: A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in exemplifying the method are described. The vectors confer apramycin resistance to sensitive Streptomyces host cells and thus provide a convenient method of selecting Streptomyces transformants. The apramycin resistance-conferring gene used in the method is an acetyltransferase aac(3)IV gene and can be isolated from E. coli K12 BE1041/pKC309 (NRRL B-15827) on an .about.1.5 kb PstI-EcoRI restriction fragment.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: June 27, 1989
    Assignee: Eli Lilly and Company
    Inventors: R. Nagaraja Rao, Richard K. Stanzak
  • Patent number: 4766066
    Abstract: The invention relates to a method and cloning vehicle for the expression of a functional polypeptide in Streptomyces. A recombinant DNA cloning vehicle was genetically engineered to bring the expression of the neomycin phosphotransferase gene under the control of the Escherichia coli bacteriophage .lambda.p.sub.L promoter.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: August 23, 1988
    Assignee: Eli Lilly and Company
    Inventors: Stuart A. Kuhstoss, R. Nagaraja Rao
  • Patent number: 4753886
    Abstract: The present invention discloses selectable, recombinant DNA shuttle vectors for use in streptomycetes and E. coli. The shuttle vectors of the present invention are present at moderately high copy number. The invention further discloses transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: June 28, 1988
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson
  • Patent number: 4698307
    Abstract: The present invention disclosed novel recombinant DNA cloning vectors including pMND1000 and vectors derived therefrom for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: October 6, 1987
    Assignee: Eli Lilly and Company
    Inventors: James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4683206
    Abstract: The present invention disclosed novel recombinant DNA cloning vectors for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: July 28, 1987
    Assignee: Eli Lilly and Company
    Inventors: James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4680265
    Abstract: A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in the method are described. The vectors confer tylosin resistance to sensitive Streptomyces host cells and thus provide a convenient method of selecting Streptomyces transformants. The novel tylosin resistance-conferring gene described can be isolated on an .about.2.6 kb KpnI restriction fragment from plasmid pSVB2. Plasmid pSVB2 can be isolated from Streptomyces lividans TK23/pSVB2 (NRRL 15880).
    Type: Grant
    Filed: September 25, 1984
    Date of Patent: July 14, 1987
    Assignee: Eli Lilly and Company
    Inventors: Virginia A. Birmingham, Eugene T. Seno
  • Patent number: 4468462
    Abstract: The present invention discloses selectable recombinant DNA cloning vectors for use in Streptomyces.
    Type: Grant
    Filed: December 22, 1982
    Date of Patent: August 28, 1984
    Assignee: Eli Lilly and Company
    Inventors: Nancy E. Malin, Jeffrey T. Fayerman, Michael D. Jones, James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4204039
    Abstract: Deoxynarasin antibiotic complex, comprising 20-deoxynarasin and 20-deoxy-epi-17-narasin, is produced by submerged aerobic fermentation of Streptomyces aureofaciens NRRL 11181. 20-Deoxynarasin and 20-deoxy-epi-17-narasin are separated and isolated by chromatography. The deoxynarasin complex, 20-deoxynarasin and 20-deoxy-epi-17-narasin are antibacterial and anticoccidial agents and also increase feed-utilization efficiency in ruminants.
    Type: Grant
    Filed: June 19, 1978
    Date of Patent: May 20, 1980
    Assignee: Eli Lilly and Company
    Inventors: Walter M. Nakatsukasa, Gary G. Marconi, Norbert Neuss, Robert L. Hamill